BIO-TECHNE Corp (TECH) shareholders
TECHNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30
Financials through Q1 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3040% above fair value
$72.80−0.02 (-0.03%)
Close on Nov 11, 2026Market cap $11.43BP/E 66.8Yield 0.44%
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
100.0%
175M of 157M shares
Institutional holders
596
130 new, 112 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 2 sales
Net sold $437.19K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (8.10%) | 12,754,784 | 8.10% | 13G (passive) amendment | Jun 30, 2026 |
| Vanguard Capital Management | 11,559,571 | 7.38% | 13G (passive) | Mar 31, 2026 |
| BlackRock, Inc. | 11,011,556 | 7.00% | 13G (passive) amendment | Jun 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TECH | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 14,025,816 | 8.93% | $990.92M | +1,761,303 | 0.01% |
| FMR LLC | 12,794,784 | 8.15% | $903.95M | +4,894,856 | 0.04% |
| Vanguard Capital Management LLC | 10,218,558 | 6.51% | $721.94M | +38,849 | 0.02% |
| Goldman Sachs Group Inc | 7,343,324 | 4.68% | $518.81M | +5,399,790 | 0.05% |
| Hbk Investments L P | 6,825,000 | 4.35% | $482.19M | New | 4.71% |
| Vanguard Portfolio Management LLC | 6,506,360 | 4.14% | $459.67M | +26,023 | 0.02% |
| Morgan Stanley | 6,374,717 | 4.06% | $450.37M | −2,158,156 | 0.02% |
| State Street Corp | 5,980,370 | 3.81% | $422.51M | +111,974 | 0.01% |
| Geode Capital Management, LLC | 5,351,464 | 3.41% | $377.54M | +239,044 | 0.02% |
| Invesco Ltd. | 4,986,424 | 3.17% | $352.29M | +397,718 | 0.03% |
| Ruane, Cunniff & Goldfarb L.P. | 3,348,841 | 2.13% | $236.60M | −43,160 | 3.68% |
| Snyder Capital Management L P | 3,163,816 | 2.01% | $223.52M | +1,281,518 | 3.86% |
| Neuberger Berman Group LLC | 2,844,692 | 1.81% | $200.98M | −496,145 | 0.13% |
| Massachusetts Financial Services Co /Ma/ | 2,746,462 | 1.75% | $194.01M | −986,786 | 0.06% |
| Mairs & Power Inc | 2,700,698 | 1.72% | $190.80M | −49,584 | 1.75% |
| Capital Research Global Investors | 2,621,890 | 1.67% | $185.24M | −566,320 | 0.03% |
| UBS Group AG | 2,478,607 | 1.58% | $175.11M | −575,736 | 0.02% |
| Dimensional Fund Advisors LP | 2,253,512 | 1.43% | $159.22M | +280,376 | 0.03% |
| Whitebox Advisors LLC | 2,100,001 | 1.34% | $148.37M | New | 1.94% |
| Sumitomo Mitsui Trust Holdings, Inc. | 2,067,324 | 1.32% | $146.06M | +13,030 | 0.08% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 596 | 175M | 100.0% | 130 / 162 | 243 / 112 | 46M | 48M |
| Q1 2026 | 585 | 177M | 100.0% | 73 / 199 | 225 / 64 | 44M | 21M |
| Q4 2025 | 585 | 172M | 100.0% | 88 / 207 | 211 / 70 | 27M | 14M |
| Q3 2025 | 577 | 160M | 100.0% | 97 / 215 | 184 / 70 | 26M | 26M |
| Q2 2025 | 556 | 159M | 100.0% | 82 / 219 | 196 / 100 | 20M | 24M |
| Q1 2025 | 578 | 163M | 100.0% | 76 / 206 | 210 / 67 | 18M | 17M |
| Q4 2024 | 577 | 162M | 100.0% | 75 / 221 | 194 / 50 | 16M | 8M |
| Q3 2024 | 563 | 155M | 99.0% | 60 / 194 | 209 / 62 | 21M | 8M |
| Q2 2024 | 572 | 157M | 100.0% | 67 / 213 | 210 / 45 | 9M | 19M |
| Q1 2024 | 555 | 168M | 100.0% | 73 / 204 | 182 / 44 | 17M | 9M |
| Q4 2023 | 531 | 160M | 100.0% | 81 / 210 | 172 / 71 | 16M | 9M |
| Q3 2023 | 530 | 153M | 97.1% | 60 / 175 | 215 / 56 | 9M | 8M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
582 funds held TECH in Q2 2026, 38% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TECH | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Contrafund | 4,989,801 | 3.18% | $352.53M | 0.20% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 4,968,867 | 3.16% | $351.05M | 0.02% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 4,056,808 | 2.58% | $286.61M | 0.02% | Jun 30, 2026 |
| SMALLCAP World Fund Inc | 3,593,129 | 2.29% | $253.85M | 0.27% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,586,562 | 2.28% | $253.39M | 0.13% | Jun 30, 2026 |
| Invesco S&P 500 Equal Weight ETF | 3,550,177 | 2.26% | $255.93M | 0.27% | Jul 31, 2026 |
| Eaton Vance Atlanta Capital SMID-Cap Fund | 2,604,519 | 1.66% | $184.01M | 2.09% | Jun 30, 2026 |
| MFS Mid Cap Growth Fund | 2,330,856 | 1.48% | $120.46M | 0.87% | May 31, 2026 |
| iShares Core S&P 500 ETF | 2,160,586 | 1.38% | $152.65M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,071,188 | 1.32% | $146.33M | 0.31% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 2,002,138 | 1.27% | $103.47M | 0.01% | May 31, 2026 |
| Select Health Care Portfolio | 1,900,000 | 1.21% | $98.19M | 1.70% | May 31, 2026 |
| Neuberger Genesis Fund | 1,852,945 | 1.18% | $95.76M | 1.30% | May 31, 2026 |
| Select Medical Technology and Devices Portfolio | 1,640,000 | 1.04% | $84.76M | 2.85% | May 31, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 1,568,630 | 1.00% | $81.07M | 0.03% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kim Kelderman | Chief Executive Officer, Director | 80,509 | 0.05% | Nov 3, 2026 |
| James Hippel | CFO | 176,720 | 0.11% | Nov 3, 2026 |
| William Geist | PRESIDENT, PROTEIN SCIENCES | 25,031 | 0.02% | Nov 2, 2026 |
| Shane Bohnen | SVP - General Counsel | 10,407 | 0.01% | Nov 2, 2026 |
| Steven C. Crouse | President - Diag & Spatial Bi | 10,237 | 0.01% | Aug 19, 2026 |
| Matthew McManus | President - Diag & Spatial Bio | 7,691 | 0.00% | Feb 3, 2026 |
| Robert V. Baumgartner | Director | 59,634 | 0.04% | Nov 2, 2026 |
| John L. Higgins | Director | 80,004 | 0.05% | Nov 2, 2026 |
| Amy E. Herr | Director | 6,006 | 0.00% | Nov 2, 2026 |
| Julie L. Bushman | Director | 11,525 | 0.01% | Nov 2, 2026 |
| Alpna Seth | Director | 18,161 | 0.01% | Nov 2, 2026 |
| Rupert Vessey | Director | 13,737 | 0.01% | Nov 2, 2026 |
| Judith V. Klimovsky | Director | 6,532 | 0.00% | Nov 2, 2026 |
| Joseph D. Keegan | Director | 18,161 | 0.01% | Nov 2, 2026 |
| Roeland Nusse | Director | 44,559 | 0.03% | Aug 27, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Kim Kelderman Chief Executive Officer, Director | Nov 1, 2026 | Tax withholding | −2,385 | $72.66 | $173.29K | 80,509 |
| James Hippel CFO | Nov 1, 2026 | Tax withholding | −5,096 | $72.66 | $370.28K | 176,720 |
| James Hippel CFO | Nov 1, 2026 | Option exercise | +11,545 | – | – | 181,816 |
| Rupert Vessey Director | Oct 29, 2026 | Award | +2,750 | – | – | 13,737 |
| Alpna Seth Director | Oct 29, 2026 | Award | +2,750 | – | – | 18,161 |
| Judith V. Klimovsky Director | Oct 29, 2026 | Award | +2,750 | – | – | 6,532 |
| Amy E. Herr Director | Oct 29, 2026 | Award | +2,750 | – | – | 5,430 |
| Joseph D. Keegan Director | Oct 29, 2026 | Award | +2,750 | – | – | 18,161 |
| John L. Higgins Director | Oct 29, 2026 | Award | +2,750 | – | – | 80,004 |
| Julie L. Bushman Director | Oct 29, 2026 | Award | +2,750 | – | – | 11,525 |
| Robert V. Baumgartner Director | Oct 29, 2026 | Award | +2,750 | – | – | 59,634 |
| John L. Higgins Director | Sep 28, 2026 | Tax withholding | −5,562 | $72.51 | $403.30K | 77,254 |
| John L. Higgins Director | Sep 28, 2026 | Option exercise | +15,940 | – | – | 82,816 |
| Robert V. Baumgartner Director | Sep 22, 2026 | Tax withholding | −5,559 | $72.55 | $403.31K | 56,884 |
| Robert V. Baumgartner Director | Sep 22, 2026 | Option exercise | +15,940 | – | – | 62,443 |
| James Hippel CFO | Aug 15, 2026 | Tax withholding | −4,423 | $72.40 | $320.23K | 170,271 |
| James Hippel CFO | Aug 15, 2026 | Option exercise | +9,980 | – | – | 174,694 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Aug 15, 2026 | Tax withholding | −2,019 | $72.40 | $146.18K | 25,031 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Aug 15, 2026 | Option exercise | +6,547 | – | – | 27,050 |
| Kim Kelderman Chief Executive Officer, Director | Aug 15, 2026 | Tax withholding | −10,955 | $72.40 | $793.14K | 82,894 |
| Kim Kelderman Chief Executive Officer, Director | Aug 15, 2026 | Option exercise | +21,736 | – | – | 93,849 |
| Shane Bohnen SVP - General Counsel | Aug 15, 2026 | Tax withholding | −1,366 | $72.40 | $98.90K | 10,407 |
| Shane Bohnen SVP - General Counsel | Aug 15, 2026 | Option exercise | +4,420 | – | – | 11,773 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Aug 15, 2026 | Tax withholding | −1,976 | $72.40 | $143.06K | 24,943 |
| William Geist PRESIDENT, PROTEIN SCIENCES | Aug 15, 2026 | Option exercise | +6,416 | – | – | 26,919 |
| Kim Kelderman Chief Executive Officer, Director | Aug 15, 2026 | Tax withholding | −10,821 | $72.40 | $783.44K | 82,762 |
| Kim Kelderman Chief Executive Officer, Director | Aug 15, 2026 | Option exercise | +21,470 | – | – | 93,583 |
| Shane Bohnen SVP - General Counsel | Aug 15, 2026 | Option exercise | +4,350 | – | – | 11,703 |
| Shane Bohnen SVP - General Counsel | Aug 15, 2026 | Tax withholding | −1,343 | $72.40 | $97.23K | 10,360 |
| Amy E. Herr Director | Aug 15, 2026 | Tax withholding | −213 | $72.40 | $15.42K | 576 |
| Amy E. Herr Director | Aug 15, 2026 | Option exercise | +589 | – | – | 789 |
| Steven C. Crouse President - Diag & Spatial Bi | Aug 15, 2026 | Option exercise | +5,423 | – | – | 12,184 |
| Steven C. Crouse President - Diag & Spatial Bi | Aug 15, 2026 | Tax withholding | −1,947 | $72.40 | $140.96K | 10,237 |
| James Hippel CFO | Aug 15, 2026 | Tax withholding | −4,310 | $72.40 | $312.04K | 170,183 |
| James Hippel CFO | Aug 15, 2026 | Option exercise | +9,779 | – | – | 174,493 |
| James Hippel CFO | Jul 29, 2026 | Option exercise | +62,068 | $47.60 | $2.95M | 215,738 |
| James Hippel CFO | Jul 29, 2026 | Tax withholding | −51,024 | $72.03 | $3.68M | 164,714 |
| Kim Kelderman Chief Executive Officer, Director | Jul 28, 2026 | Tax withholding | −28,686 | $72.07 | $2.07M | 72,113 |
| Kim Kelderman Chief Executive Officer, Director | Jul 28, 2026 | Option exercise | +35,000 | $47.60 | $1.67M | 100,799 |
| Shane Bohnen SVP - General Counsel | Jul 23, 2026 | Tax withholding | −344 | $71.77 | $24.69K | 7,353 |
| Shane Bohnen SVP - General Counsel | Jul 23, 2026 | Option exercise | +448 | $47.60 | $21.32K | 7,697 |
| Steven C. Crouse President - Diag & Spatial Bi | Jun 2, 2026 | Tax withholding | −216 | $49.77 | $10.75K | 6,761 |
| Steven C. Crouse President - Diag & Spatial Bi | Jun 2, 2026 | Option exercise | +600 | – | – | 6,977 |
| Amy E. Herr Director | May 8, 2026 | Sale | −6,636 | $48.28 | $320.39K | 200 |
| Amy E. Herr Director | May 8, 2026 | Option exercise | +6,636 | $47.60 | $315.87K | 6,836 |
| Shane Bohnen SVP - General Counsel | May 5, 2026 | Tax withholding | −7,055 | $56.68 | $399.88K | 7,249 |
| Shane Bohnen SVP - General Counsel | May 5, 2026 | Option exercise | +8,400 | $47.60 | $399.84K | 14,304 |
| James Hippel CFO | May 5, 2026 | Tax withholding | −56,955 | $56.68 | $3.23M | 153,670 |
| James Hippel CFO | May 5, 2026 | Option exercise | +62,000 | $47.60 | $2.95M | 210,625 |
| Kim Kelderman Chief Executive Officer, Director | May 5, 2026 | Option exercise | +26,692 | $47.60 | $1.27M | 89,750 |
| Kim Kelderman Chief Executive Officer, Director | May 5, 2026 | Tax withholding | −23,951 | $56.68 | $1.36M | 65,799 |
| Steven C. Crouse President - Diag & Spatial Bi | May 1, 2026 | Tax withholding | −311 | $55.02 | $17.11K | 6,337 |
| Steven C. Crouse President - Diag & Spatial Bi | May 1, 2026 | Option exercise | +794 | – | – | 6,688 |
| Kim Kelderman Chief Executive Officer, Director | Apr 22, 2026 | Tax withholding | −1,363 | $58.58 | $79.84K | 63,058 |
| Kim Kelderman Chief Executive Officer, Director | Apr 22, 2026 | Option exercise | +11,344 | – | – | 64,421 |
| James Hippel CFO | Apr 22, 2026 | Option exercise | +62,000 | – | – | 204,722 |
| James Hippel CFO | Apr 22, 2026 | Tax withholding | −56,097 | $58.58 | $3.29M | 148,625 |
| Kim Kelderman Chief Executive Officer, Director | Apr 14, 2026 | Tax withholding | −32,088 | $58.66 | $1.88M | 53,077 |
| Kim Kelderman Chief Executive Officer, Director | Apr 14, 2026 | Option exercise | +36,500 | – | – | 85,165 |
| Shane Bohnen SVP - General Counsel | Apr 3, 2026 | Tax withholding | −740 | $53.13 | $39.32K | 5,904 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
4.92%
8M shares short
Days to cover
2.7
At 3M shares a day
Change since last report
+2.0%
From 8M shares
Short volume, 20 days
38.0%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Bio-Techne's stock actually held short. Settlement fails (shares not delivered on time) peaked at 48,379 shares on Sep 22, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Joshua Molho Director | May 8, 2026 | 6,636 | $320.42K | May 8, 2026 | Exercise of options under a registered plan |
| Joshua Molho Director | Feb 17, 2026 | 1,976 | $116.79K | Feb 17, 2026 | Previously Exercised Options |
| Robert V. Baumgartner4731 Bonita Bay Boulevard Director | Aug 25, 2025 | 17,040 | $957.85K | Aug 25, 2025 | Exercise of options under a registered plan |
| Roeland Nusse Director | Aug 25, 2025 | 17,040 | $960.39K | Aug 25, 2025 | Stock Option Exercise |
| Joshua Molho Officer | Jun 9, 2025 | 1,280 | $63.70K | Jun 9, 2025 | Exercise of options under a registered plan |
| Joshua Molho Domestic Partner of Director | Feb 14, 2025 | 1,860 | $122.69K | Feb 14, 2025 | Restricted stock vesting under a registered plan |
| Kim Kelderman Director, Officer | Jan 27, 2025 | 13,392 | $1.03M | Jan 27, 2025 | Exercise of Stock Options |
| Robert V. Baumgartner Director | Aug 8, 2024 | 16,000 | $1.15M | Aug 8, 2024 | Exercise of options under a registered plan |
| John L. Higgins Director | May 14, 2024 | 4,000 | $335.38K | May 14, 2024 | Exercise of options under a registered plan |
| Roeland Nusse Director | Mar 7, 2024 | 10,400 | $800.63K | Mar 7, 2024 | Stock Option Exercise and Stock Dividends |
| Roeland Nusse Director | Aug 30, 2023 | 8,939 | $717.96K | Aug 30, 2023 | Exercise of options under a registered plan |
| Kummeth Charles R. Officer | Jul 21, 2023 | 80,000 | $7.07M | Jul 21, 2023 | Stock Award |
| Charles Kummeth Officer | Jun 6, 2023 | 50,000 | $4.15M | Jun 6, 2023 | Stock Option Exercise |
See a number that looks wrong?